Infection‐related mortality · people with chemotherapy‐induced febrile neutropenia
Benefits and harms of CSF plus antibiotics showed no clear difference in infection‐related mortality compared with antibiotics alone (low certainty).
1 finding from 1 review
People hospitalized for > 10 days · people with chemotherapy‐induced febrile neutropenia
Benefits and harms of CSF plus antibiotics may leads to lower people hospitalized for > 10 days compared with antibiotics alone (low certainty).
1 finding from 1 review
Time to recovery from fever (lower values signify better outcomes) · people with chemotherapy‐induced febrile neutropenia
Benefits and harms of CSF plus antibiotics showed no clear difference in time to recovery from fever (lower values signify better outcomes) compared with antibiotics alone (low certainty).
1 finding from 1 review
Time to withdrawal from ATB (lower values signify better outcomes) · people with chemotherapy‐induced febrile neutropenia
Benefits and harms of CSF plus antibiotics showed no clear difference in time to withdrawal from ATB (lower values signify better outcomes) compared with antibiotics alone (low certainty).
1 finding from 1 review
Deep vein thrombosis · people with chemotherapy‐induced febrile neutropenia
Benefits and harms of CSF plus antibiotics showed no clear difference in deep vein thrombosis compared with antibiotics alone (low certainty).
1 finding from 1 review
Postoperative pain at 6 hours VAS from 0 to 10 · women with uterine fibroids
1 finding from 1 review
Postoperative pain at 24 hours VAS from 0 to 10 · women with uterine fibroids
1 finding from 1 review
Postoperative pain at 48 hours VAS from 0 to 10 · women with uterine fibroids
1 finding from 1 review
Perioperative in‐hospital adverse events; unscheduled return to theatre · women with uterine fibroids
Laparoscopic myomectomy showed no clear difference in perioperative in‐hospital adverse events; unscheduled return to… compared with open myomectomy (all types) (low certainty).
1 finding from 1 review
Perioperative in‐hospital adverse events; laparoconversion · women with uterine fibroids
Laparoscopic myomectomy showed no clear difference in perioperative in‐hospital adverse events; laparoconversion compared with open myomectomy (all types) (moderate certainty).
1 finding from 1 review
Perioperative in‐hospital adverse events; injury to pelvic organs · women with uterine fibroids
Laparoscopic myomectomy showed no clear difference in perioperative in‐hospital adverse events; injury to pelvic organs compared with open myomectomy (all types) (moderate certainty).
1 finding from 1 review
In‐hospital adverse events; postoperative fever · women with uterine fibroids
Laparoscopic myomectomy probably leads to lower in‐hospital adverse events; postoperative fever compared with open myomectomy (all types) (moderate certainty).
1 finding from 1 review
Disease-free survival · people with Rectal Cancer
Laparoscopic showed no clear difference in disease‐free survival at 5 years compared with open total mesorectal excision (moderate certainty).
1 finding from 1 review
Overall survival at 5 years · people with Rectal Cancer
Laparoscopic showed no clear difference in overall survival at 5 years compared with open total mesorectal excision (moderate certainty).
1 finding from 1 review
Local recurrence · people with Rectal Cancer
Laparoscopic showed no clear difference in local recurrences compared with open total mesorectal excision (moderate certainty).
1 finding from 1 review
Lymph nodes retrieved · people with Rectal Cancer
1 finding from 1 review
CRM positivity · people with Rectal Cancer
Laparoscopic showed no clear difference in CRM positivity compared with open total mesorectal excision (moderate certainty).
1 finding from 1 review
Total morbidity · people with Rectal Cancer
Laparoscopic showed no clear difference in 30‐day morbidity (total) compared with open total mesorectal excision (moderate certainty).
1 finding from 1 review
Length of hospital stay · people with Rectal Cancer
1 finding from 1 review
Reduction of snoring · Children and adolescents (over 80% aged 16 years or younger at treatment start) with anterior open bite (lack of vertical overlap or…
The review found no eligible studies for this question.
1 finding from 1 review